US Broker Ratings

Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 718% Upside in Biotechnology

Investors with an appetite for high-risk, high-reward opportunities might find Humacyte, Inc. (NASDAQ: HUMA) an intriguing candidate. Operating within the biotechnology sector, Humacyte stands out with..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring 64% Potential Upside Amidst Strong Revenue Growth

Organogenesis Holdings Inc. (NASDAQ: ORGO), a leader in regenerative medicine, is making waves in the healthcare sector with its advanced wound care and surgical products. As..

Prothena Corporation plc (PRTA) Stock Analysis: A Biotech Firm with 112.91% Potential Upside

Prothena Corporation plc (NASDAQ: PRTA) has been drawing considerable attention from investors in the biotechnology sector, thanks to its promising pipeline and a potential upside of..

EyePoint, Inc. (EYPT) Stock Analysis: A Biotech Gem with Nearly 98% Upside Potential

Investors seeking high-growth opportunities in the biotechnology sector might find EyePoint, Inc. (NASDAQ: EYPT) particularly compelling. With a focus on developing groundbreaking therapeutics for retinal diseases,..

Inventiva S.A. (IVA) Stock Analysis: 229% Potential Upside Captivates Investors

Investors with a keen eye on the biotechnology sector should take note of Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company based in Daix, France. Specializing in..

Cogent Biosciences, Inc. (COGT) Stock Analysis: Potential 38% Upside as Analysts Show Strong Buy Interest

Cogent Biosciences, Inc. (NASDAQ: COGT) is capturing the attention of investors with its significant potential upside and robust analyst support. As a biotechnology company focused on..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a 25% Upside Potential in the Biotech Space

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company, is turning heads in the investment community with its promising advancements in precision medicine. With a market..

Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a 72% Potential Upside Amid Strong Buy Ratings

Rapport Therapeutics, Inc. (NASDAQ: RAPP) is emerging as a noteworthy player in the biotechnology industry with its focus on innovative treatments for central nervous system disorders...

Atai Beckley N.V (ATAI): Investor Outlook on a Biotech Powerhouse with 203% Potential Upside

Atai Beckley N.V. (NASDAQ: ATAI) is capturing attention across the investment landscape with its substantial 203% potential upside, as indicated by analyst target prices. As a..

Auna SA (AUNA) Stock Analysis: Exploring a Potential 111.72% Upside in the Healthcare Sector

Auna SA (AUNA), a prominent player in the healthcare sector, operates a network of hospitals and clinics across Mexico, Peru, and Colombia. Based in Luxembourg, the..

Maravai LifeSciences Holdings (MRVI) Investor Outlook: Navigating the Biotech Terrain with a 20.88% Upside Potential

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stands as a noteworthy player within the biotechnology industry. With a market capitalization of $1.19 billion, Maravai operates primarily in..

Celcuity Inc. (CELC) Stock Report: A Biotechnology Pioneer with a 10.79% Potential Upside

Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company headquartered in Minneapolis, is making waves in the healthcare sector with its innovative approach to cancer treatment. Primarily..

Standard BioTools Inc. (LAB) Stock Analysis: Exploring a Potential 21% Upside in the Medical Devices Sector

Standard BioTools Inc. (NASDAQ: LAB) operates at the forefront of the healthcare sector, specializing in the development and sale of sophisticated instrumentation, consumables, and services for..

Castle Biosciences, Inc. (CSTL) Stock Analysis: A Healthcare Innovator with Strong Buy Ratings and Promising Target Price

Castle Biosciences, Inc. (NASDAQ: CSTL) is making waves in the healthcare sector, particularly within the diagnostics and research industry. With a market capitalization of $1.14 billion,..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Exploring the 203% Upside Potential in Biotechnology

Bicycle Therapeutics plc (NASDAQ: BCYC), a UK-based biotechnology firm, is capturing investor attention with a staggering potential upside of 203.67%. This figure, combined with the company’s..

Upstream Bio, Inc. (UPB) Stock Analysis: Biotech Innovator with a 75% Potential Upside

Upstream Bio, Inc. (UPB) has emerged as a promising player in the biotechnology sector, particularly within the niche of inflammatory disease treatments. With its focus on..

Personalis, Inc. (PSNL) Stock Analysis: Exploring a 38% Upside Potential in the Healthcare Diagnostics Sector

Investors with an eye on the healthcare diagnostics sector might find Personalis, Inc. (NASDAQ: PSNL) an intriguing opportunity, especially given the significant 38.19% potential upside based..

REGENXBIO Inc. (RGNX) Investor Outlook: Exploring a 110.86% Upside Potential in Gene Therapy Innovation

REGENXBIO Inc. (NASDAQ: RGNX) stands out in the biotechnology sector with its innovative approach to gene therapy, particularly through its proprietary NAV Technology Platform. This clinical-stage..

Surmodics, Inc. (SRDX) Stock Report: Navigating Challenges with Innovative Medical Solutions

Surmodics, Inc. (NASDAQ: SRDX), a key player in the healthcare sector specializing in medical devices, is certainly an intriguing entity for investors with a penchant for..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring a 99.97% Potential Upside

ArriVent BioPharma, Inc. (AVBP), a burgeoning player in the biotechnology sector, is capturing investor attention with its promising pipeline and a staggering potential upside of 99.97%...

US Broker Ratings

US Broker Ratings

FTSE 100

Funds